

Special Issue

Nanomedicines in Cancer Therapy, 2nd Edition

Message from the Guest Editor

Despite many advanced treatment methods in the field of oncology, cancer remains a deadly disease globally. The administration of anticancer drugs is the most common treatment approach for various cancers. However, most of the currently available anticancer drugs suffer from limitations, including multi-drug resistance, drug toxicity, poor drug bioavailability, etc. Nanomedicines involve the application of nanotechnology for the monitoring, diagnosis, and treatment of different cancers. Nanomedicines have been widely explored in preclinical studies; they provide improved therapeutic outcomes compared to conventional anticancer drugs. There are currently some nanomedicine formulations and devices available on the market and many more undergoing clinical trials and development. This Special Issue focuses on the current status and prospects of nanomedicines based on preclinical and clinical studies for the treatment of cancer.

Guest Editor

Dr. Sibusiso Alven

Department of Chemistry, Nelson Mandela University, P.O. Box 77000,
Port Elizabeth 6001, South Africa

Deadline for manuscript submissions

20 August 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/26211

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).